Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|December 23, 2009
FDA Opens Mexico City Office
Author(s)Angie Drakulich
The US Food and Drug Administration opened another foreign office, this time in Mexico City.
Advertisement
The US Food and Drug Administration opened another foreign office on Dec. 15, 2009, this time in Mexico City. The new post marks the agency’s third location in Latin America and its tenth international office to open during the past 13 months, according to an FDA
“The opening of this office represents an important step as we redesign our product safety strategy,” said FDA Commissioner Margaret A. Hamburg, in the release. Mexico City employees will work with their Mexican government counterparts to harmonize regulations and develop other collaborative initiatives such as information sharing.
“FDA staff will work with industry in Mexico as well,” said Murray M. Lumpkin, deputy commissioner for international programs in the release. “Their activities will include providing technical advice and working with government agencies and the private sector to develop certification programs.”
Other FDA international posts are in China, India, Europe, and Latin America. Other Latin American offices are located in Santiago, Chile, and San José, Costa Rica.
See related
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
5